Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in T2DM and Heart Failure
NCT03190798Phase 4Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Sep 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure (HF) comparing Canagliflozin Group with Placebo Group (2 arms). Primary endpoint: Pulmonary Capillary Wedge Pressure at 6 hours. Planned start Sep 2017; status: withdrawn.
02
Drugs
canagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03190798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190798.